Skip to main content
SpringerLink
Log in

Supportivtherapie bei Urogenitaltumoren

Diagnostik und Therapie häufiger Komplikationen

Supportive therapy of urogenital tumors

Diagnostic and therapy of common complications

  • Leitthema
  • Published:
Der Urologe Aims and scope Submit manuscript

Zusammenfassung

Im Rahmen der systemischen Zytostatikatherapie und bei fortgeschrittenen Tumorerkrankungen kann es zu schwerwiegenden, die Lebensqualität erheblich beeinträchtigenden und teils lebensbedrohlichen Komplikationen kommen. Der Artikel gibt einen Überblick über die aktuelle Literatur zur Diagnostik und Therapie der malignomassoziierten Hyperkalzämie, Anämie und Thromboembolie sowie Empfehlungen zum Umgang mit der therapieassoziierten Neutropenie.

Abstract

Within the framework of systemic therapy with cytostatic agents and advanced stages of tumor diseases, therapy-induced and disease-related complications can severely impair the quality of life. This article gives a brief synopsis of the current literature on the diagnosis and therapy concerning anemia thrombotic events and tumor-related hypercalcemia as well as recommendations on treating therapy-associated neutropenia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ay C, Vormittag R, Dunkler D et al (2008) Predicitive value of d-dimer levels for venous thromboembolism in cancer patients: results from the vienna cancer and thrombosis study (CATS). Blood 112: 2703–2708

    Article  PubMed  Google Scholar 

  2. Bennett CL, Silver SM, Djulbegovic B et al (2008) Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299:914–924

    Article  PubMed  Google Scholar 

  3. Blom JW, Doggen CJ, Osanto S et al (2005) Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293:715–722

    Article  PubMed  Google Scholar 

  4. Bohlius J, Wilson J, Seidenfeld J et al (2006) Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 3:CD003407

    PubMed  Google Scholar 

  5. Chew HK, Wun T, Harvey D et al (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166:458–464

    Article  PubMed  Google Scholar 

  6. Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198–4214

    Article  PubMed  Google Scholar 

  7. Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998

    Article  PubMed  Google Scholar 

  8. Gafter-Gvili A, Paul M, Fraser A et al (2007) Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: systematic review and meta-analysis. J Antimicrob Chemother 59:5–22

    Article  PubMed  Google Scholar 

  9. Garcia-Carbonero R, Mayordomo JI, Tornamira MV et al (2001) Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93:31–38

    Article  PubMed  Google Scholar 

  10. Geerts WH, Bergqvist D, Pineo GF et al (2008) Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, 8th edn. Chest 133:381–453

    Article  Google Scholar 

  11. Kakkar AK, Lemoine NR, Scully MF et al (1995) Tissue factor expression correlates with histological grade in human pancreatic cancer. Br J Surg 82:1101–1104

    Article  PubMed  Google Scholar 

  12. Khorana AA, Francis CW, Culakova E et al (2007) Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 5:632–634

    Article  PubMed  Google Scholar 

  13. Kuderer NM, Dale DC, Crawford J et al (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158–3167

    Article  PubMed  Google Scholar 

  14. Leibovici L, Paul M, Cullen M et al (2006) Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions. Cancer 107:1743–1751

    Article  PubMed  Google Scholar 

  15. Lipton A, Colombo-Berra A, Bukowski RM et al (2004) Skeletal complications in patients with bone metastases from renal cell carcinoma and therapeutic benefits of zoledronic acid. Clin Cancer Res 10:6397–6403

    Article  Google Scholar 

  16. Lyman GH, Khorana AA, Falanga A et al (2007) American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490–5505

    Article  PubMed  Google Scholar 

  17. Maxwell RA, Chavarria-Aguilar M, Cockerham WT et al (2002) Routine prophylactic vena cava filtration is not indicated after acute spinal cord injury. J Trauma 52:902–906

    Article  PubMed  Google Scholar 

  18. Noble SI, Shelley MD, Coles B et al (2008) Management of venous thromboembolism in patients with advanced cancer: a systematic review and meta-analysis. Lancet Oncol 9:577–584

    Article  PubMed  Google Scholar 

  19. Papapetrou PD (2009) Bisphosphonate-associated adverse events. Hormones (Athens) 8:96–110

    Google Scholar 

  20. Prandoni P, Lensing AW, Piccioli A et al (2002) Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488

    Article  PubMed  Google Scholar 

  21. Rustemeyer J, Bremerich A (2009) Bisphosphonate-associated osteonecrosis of the jaw: what do we currently know? A survey of knowledge given in the recent literature. Clin Oral Investig 67:107–119

    Google Scholar 

  22. Saad F, Chi K, Fleshner N (2004) The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol 11:2376–2382

    PubMed  Google Scholar 

  23. Saad F, Lipton A (2005) Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU Int 96:964–969

    Article  PubMed  Google Scholar 

  24. Sack GH Jr, Levin J, Bell WR (1977) Trousseau’s syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: clinical, pathophysiologic, and therapeutic features. Medicine (Baltimore) 56:1–37

    Google Scholar 

  25. Smith RE Jr, Aapro MS, Ludwig H et al (2008) Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26:1040–1050

    Article  PubMed  Google Scholar 

  26. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187–3205

    Article  PubMed  Google Scholar 

  27. Stewart AF (2005) Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 352:373–379

    Article  PubMed  Google Scholar 

  28. Timmer-Bonte JN, De Boo TM, Smit HJ et al (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974–7984

    Article  PubMed  Google Scholar 

  29. Varki A (2007) Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood 110:1723–1729

    Article  PubMed  Google Scholar 

  30. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178–1184

    Article  PubMed  Google Scholar 

  31. Wegmann D (1981) Paraneoplastische Thrombose. VASA 10:111–114

    PubMed  Google Scholar 

  32. Weiss G, Goodnough LT (2005) Anemia of chronic disease. N Engl J Med 352:1011–1023

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Klinik für Innere Medizin III, Universitätsklinikum, Albert-Einstein-Straße 23, 89081, Ulm, Deutschland

    M. Bommer & M. Kull

Authors
  1. M. Bommer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Kull
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Bommer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bommer, M., Kull, M. Supportivtherapie bei Urogenitaltumoren. Urologe 48, 1273–1282 (2009). https://doi.org/10.1007/s00120-009-2104-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00120-009-2104-3

Schlüsselwörter

Keywords

Search

Navigation